Single
PreclinicalSmall molecule
Single is one of 43 small molecule programs targeting Meningioma. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Meningioma
#DrugCompanyPhaseTrials
1Cyklokapron
AAmring
Approved
Signifor
RRECORDATI GROUP
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Mifeprex
DDanco
Phase 3
Gleevec
NovartisPhase 2
Afinitor
NovartisPhase 2
Keytruda
Merck & Co.Phase 2
Sutent
PfizerPhase 2
Stivarga
BayerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Meningioma1 trial
Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection
Unknown status·—·N/A·NCT05230381·228 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Single. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details